Compare · JNJ vs NBP
JNJ vs NBP
Side-by-side comparison of Johnson & Johnson (JNJ) and NovaBridge Biosciences (NBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and NBP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 4100.8x NBP ($148.8M).
- JNJ has been more active in the news (11 items in the past 4 weeks vs 4 for NBP).
- JNJ has more recent analyst coverage (25 ratings vs 1 for NBP).
- Company
- Johnson & Johnson
- NovaBridge Biosciences
- Price
- $255.53+0.88%
- $1.27-2.68%
- Market cap
- $610.38B
- $148.8M
- 1M return
- -5.45%
- -
- 1Y return
- +31.89%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
Latest NBP
- SEC Form 6-K filed by NovaBridge Biosciences
- Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
- Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
- NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
- Chief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,828 worth of Ordinary Shares (8,209 units at $0.71), increasing direct ownership by 10% to 173,427 units (SEC Form 4)
- Chief Bus. Development Officer Cao Sean Wuxiong sold $79,904 worth of Ordinary Shares (107,978 units at $0.74), decreasing direct ownership by 29% to 266,467 units (SEC Form 4) (for tax liability)
- SEC Form 3 filed by new insider Dewhurst Martin William
- Chief Bus. Development Officer Cao Sean Wuxiong converted options into 339,372 units of Ordinary Shares, increasing direct ownership by 968% to 374,445 units (SEC Form 4)
- SEC Form 6-K filed by NovaBridge Biosciences
- SEC Form 6-K filed by NovaBridge Biosciences